Clinical trials: Trifluridine and Tipiracil
Refractory Metastatic Colorectal Cancer
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patients with colorectal cancer that has spread to the liver is safe and…
- Trial name
- DEL-LIVER (NCT06607458)
- Testing
- Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil plus Bevacizumab Alone
- Where
- 20 sites in United States, Czechia and 7 more
- Volunteers
- 90 people
- Sponsor
- Delcath Systems Inc.
Metastatic Colorectal Cancer
A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) of rivoceranib when used in combination with trifluridine/tipiracil in participants with mCRC and to assess progression-free survival (PFS) in…
- Trial name
- NCT04073615
- Testing
- Rivoceranib, Trifluridine/Tipiracil
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Elevar Therapeutics
Solid Tumor Cancer
Bioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in Humans
The test formulation of Trifluridine and Tipiracil Tablets (20 mg) is bioequivalent to the reference formulation (Lonsurf®) in Chinese patients with solid tumors under fed and fasting conditions.
- Trial name
- NCT07492173
- Testing
- Trifluridine and Tipiracil Tablets, Lonsurf®
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Metastatic Colorectal Cancer
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in…
- Trial name
- NCT05608044
- Testing
- Botensilimab, Balstilimab, Standard of Care
- Where
- 65 sites in United States, Belgium and 6 more
- Volunteers
- 234 people
- Sponsor
- Agenus Inc.
Refractory Metastatic Colorectal Cancer
Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients
This study is designed as an international, open-label, controlled two-arm, randomized phase III comparison study evaluating the efficacy and safety of trifluridine/tipiracil in combination with bevacizumab versus…
- Trial name
- SUNLIGHT (NCT04737187)
- Testing
- Trifluridine/Tipiracil, Bevacizumab
- Where
- 99 sites in United States, Austria and 12 more
- Volunteers
- 492 people
- Sponsor
- Taiho Oncology, Inc.
Colorectal Cancer
Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients
Trifluridine and Tipiracil Tablets is a nucleoside anti-metabolic and anti-cancer compound developed by Taiho (Dapeng) Co., Ltd., Japan, for the treatment of advanced colorectal cancer that inoperable resection, and progressed or…
- Trial name
- NCT03974594
- Testing
- Trifluridine and Tipiracil Tablets, TAS-102
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Metastatic Colorectal Cancer
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an…
- Trial name
- NCT07549412
- Testing
- Precemtabart tocentecan, Bevacizumab, Trifluridine/Tipiracil (FTD-TPI)
- Where
- 92 sites in United States, Argentina and 16 more
- Volunteers
- 1,020 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Colorectal Cancer
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared…
- Trial name
- AndroMETa-CRC (NCT07525206)
- Testing
- Telisotuzumab adizutecan, Bevacizumab, Trifluridine/Tipiracil
- Where
- 88 sites in United States, Belgium and 8 more
- Volunteers
- 990 people
- Sponsor
- AbbVie
Colorectal Neoplasms
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
The purpose of this study is to evaluate relatlimab in combination with nivolumab, administered as a fixed-dose combination (nivolumab-relatlimab FDC, also referred to as BMS-986213) for the treatment of non-microsatellite…
- Trial name
- RELATIVITY-123 (NCT05328908)
- Testing
- Nivolumab-relatlimab FDC, Regorafenib, TAS-102
- Where
- 139 sites in United States, Argentina and 20 more
- Volunteers
- 769 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Colorectal Cancer (mCRC)
An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions
This is an observational study using data that has been collected from participants who received their usual treatments. Metastatic colorectal cancer (mCRC) is a cancer of the colon (large bowel) or the rectum (lowest part of the…
- Trial name
- STAR-T (NCT05839951)
- Testing
- Regorafenib (BAY73-4506, Stivarga®), TAS-102 (trifluridine and tipiracil, Lonsurf®), Bevacizumab
- Where
- United States
- Volunteers
- 818 people
- Sponsor
- Bayer
Colorectal Cancer (CRC)
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated colorectal cancer (CRC) receiving sotorasib 240 mg once daily (QD) and…
- Trial name
- CodeBreak300 (NCT05198934)
- Testing
- Sotorasib, Panitumumab, Trifluridine and Tipiracil
- Where
- 105 sites in United States, Australia and 10 more
- Volunteers
- 160 people
- Sponsor
- Amgen
Metastatic Colorectal Cancer (CRC), Recurrent Colorectal Cancer
Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer
The objective of this multi-center, single-group, open-label Phase Ib/II study is to evaluate the safety, pharmacokinetics, and efficacy of nelmastobart in combination with trifluridine/tipiracil and bevacizumab in metastatic or…
- Trial name
- NCT06873763
- Testing
- Nelmastobart 800 mg+Trifluridine/Tipiracil+ Bevacizumab
- Where
- 5 sites in South Korea
- Volunteers
- 52 people
- Sponsor
- STCube, Inc.
Refractory Metastatic Colorectal Cancer
A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
The primary goal of Phase Ib Study is to evaluate the safety of Suvemcitug in combination with trifluridine/tipiracil tablets in colorectal cancer participants.
- Trial name
- NCT07361003
- Testing
- Suvemcitug injection, trifluridine/tipiracil tablets
- Where
- 6 sites in China
- Volunteers
- 464 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Metastatic Colorectal Cancer (mCRC)
CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen
This is an open label, randomized, two arm, multi-center study to explore the effect of leronlimab on the overall response rate/ overall survival and safety and tolerability when used in combination with trifluridine and…
- Trial name
- CLOVER (NCT06699836)
- Testing
- 350 mg leronlimab, 700 mg leronlimab, 200 mg pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- CytoDyn, Inc.
Non-Small Cell Lung Cancer, Advanced Solid Tumors
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to…
- Conditions
- Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer
- Trial name
- NCT05029882
- Testing
- ABBV-400, Trifluridine/Tipiracil, Bevacizumab
- Where
- 82 sites in United States, Australia and 8 more
- Volunteers
- 520 people
- Sponsor
- AbbVie
Metastatic Colorectal Cancer
CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer
HS-CA102N-103 is a Phase 2, randomized, open label study to evaluate efficacy, safety, and tolerability of CA102N combined with trifluridine/tipiracil (TAS-102) compared to bevacizumab combined with TAS-102 in subjects with…
- Trial name
- NCT06039202
- Testing
- CA102N, TAS-102, Bevacizumab
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Holy Stone Healthcare Co., Ltd
Colorectal Cancer
Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia
To compare the effects of TAS-102 with placebo in patients with metastatic colorectal cancer refractory or intolerable to standard chemotherapies.
- Trial name
- TERRA (NCT01955837)
- Testing
- TAS-102
- Where
- 4 sites in China, South Korea and 1 more
- Volunteers
- 406 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Metastatic Colorectal Cancer
Trifluridin/tipirACil in MeTastatIc Colorectal Cancer
A non-interventional, prospective, open, multicenter study in Germany in patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies and with…
- Trial name
- TACTIC (NCT03665506)
- Testing
- Trifluridin/Tipiracil
- Where
- Germany
- Volunteers
- 315 people
- Sponsor
- Servier
Metastatic Colorectal Cancer, Colorectal Cancer Metastatic
Sym004 Versus TAS-102 in Patients With mCRC
This is a Phase 3, randomized, open-label, 2-arm trial designed to evaluate overall survival (OS) following treatment with Sym004, an investigational medicinal product (IMP), versus TAS-102 (trifluridine/tipiracil), a comparator…
- Conditions
- Metastatic Colorectal Cancer, Colorectal Cancer Metastatic, Carcinoma
- Trial name
- NCT03717038
- Testing
- Sym004, TAS-102
- Sponsor
- Symphogen A/S
Advanced or Metastatic Solid Tumors, Advanced or Metastatic Colorectal Cancer (mCRC)
First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors
Study HS-CA102N-101 is a phase 1, two part (dose escalation, dose expansion), multicenter, non-randomized, open-label, multiple dose, first-in-human study of CA102N monotherapy and of CA102N combined with trifluridine/tipiracil…
- Trial name
- NCT03616574
- Testing
- CA102N, LONSURF
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Holy Stone Healthcare Co., Ltd